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1. Introduction 
Haemolytic-Uraemic Syndrome (HUS) was first described in 1955 by Gasser (Pérez del 
Campo et al., 2000) and defined as a multi-systemic syndrome, due to the association of 
microangyopathic haemolytic anemia, thrombopenia and multiorganic aggression. HUS 
affects mainly kidneys and leads to acute renal failure with high levels of urea and creatinin; 
it often involves digestive and central nervous systems. Central nervous system (CNS) 
lesions, typically at the basal ganglia, may also affect cortico-subcortical areas and in so 
doing determines motor and neurocognitive outcome, and modify the patients’ quality of 
life. 
Incidence of HUS varies among continents, highly influenced by migration movements, and 
it is estimated to be around 18/100,000 in children younger than 5 years old. Some 
countries, like Argentina and South Africa, are considered “endemic”, with a steady and 
relatively high incidence of HUS during all the seasons of the year; other areas, such as 
Canada, most of the European countries, and the west coast of the USA, are said to be 
“epidemic”, with sporadic cases and a lower incidence of HUS compared to Latin America 
and Africa during most of the year, but with self-limited relapses during summertime 
(Exeni, 2001). 
HUS etiology is diverse and physiopathologic mechanisms are not yet well known, but 
infective microorganisms are frequently involved, especially Escherichia coli, serotype 
O15:H7; this bacteria is able to produce a toxic protein (vero-toxin –VT- or Shiga-toxin –Stx), 
which “recognizes” the endothelial cells and provokes an endothelial lesion (Scheiring, 
2010). Other bacteria seem to be involved in different cases of HUS, like Salmonella enteritidis 
and Streptococcus pneumoniae (De Loos et al., 2002; Prestidge & Wong, 2009). Mutations in 
genes coding for different components of the complement system seem to be a risk factor for 
HUS (Skerka et al., 2009). However, the etiologic agent remains unidentified in most 
patients.  
Clinical presentation in the acute phase includes acute renal failure (100% of patients), often 
high blood pressure (HBP) due to a volume surcharge (35-40% of patients), and neurological 
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symptoms such as irritability, drowsiness, seizures, cortical blindness, hemiparesis or coma, 
in up to 35-50% of patients (Montoliu, 1989). These symptoms may be a consequence of 
different disturbances: metabolic distress (hyponatremia, hyperglycemia, acidosis, fluid 
imbalance), HBP itself, or CNS microangyopathy. Pancreatic failure and heart involvement 
are less frequent during the acute phase of HUS (2% of patients). 
HUS treatment is based on hydro-electrolytic management: peripheral and central venous 
pressure must be monitored and cardiac function must be closely controlled; renal function 
control is especially important, as well as caloric intake adjustment. Neurologic evaluation 
at the acute phase and during follow-up is crucial to diagnose CNS damage and prevent 
medium- and long-term sequelae.  
No complementary tests have yet been developed to help the clinician in establishing a 
medium- or long-term prognosis in patients with HUS presenting with neurologic 
symptoms. Although during the 1980s some authors observed a good clinical outcome in 
patients with microangyopathic lesions (Steinborn et al., 2004), few references have reported 
long-term follow-up in these patients. Over the last 20 years, some cases of posterior 
reversible leuko-encephalopathy syndrome of subacute onset (presenting with drowsiness, 
lethargy, visual disturbance or seizures) have been described in the context of HUS, 
sometimes not even associated with HBP (Bennett et al., 2003; Gómez-Lado et al., 2007; 
Kitamura et al., 2010). 
Prognosis factors previously described in different series of patients (Cimolai et al., 1992 ; 
Roche et al. 2008), including patient age, acute gastroenteritis symptoms, etiologic agent, 
seizures at onset, CNS images at the acute phase and neurofunctional tests performance, are 
reviewed below; clinical course during follow-up and long-term outcome of HUS patients 
with neurological symptoms are also analyzed.  
2. Material and methods 
Over the last 30 years (1981-2011), a series of 64 patients (29 boys and 35 girls) have 
presented with HUS in our hospital. Clinical charts of children with neurological symptoms 
during the acute phase were reviewed, including: 
- Clinical data: age at onset, male/female gender, clinical presentation as infectious 
disease (acute gastroenteritis); “D+” nomenclature is internationally accepted to define 
acute gastroenteritis history, not regarding infectious agent identification. “D-“ is used 
if acute gastrointestinal infection history was not present. 
- Laboratory tests (data not shown but available upon request). 
- Infectious agent: Escherichia coli, Salmonella enteritidis, Streptococcus pneumoniae, etc.  
- Neurological symptoms: seizures, drowsiness, irritability, visual disturbances and 
paresia. 
- Electrophysiological findings in video-electroencephalogram (video-EEG), visual 
evoked potentials (VEP) and brainstem evoked auditory response (BEAR), during the 
acute phase and along follow-up. 
- Brain perfusion: Medium brain artery (MBA) Doppler ultrasound (US). 
- Eye funduscopy at the acute phase and during follow-up. 
- Neuroimaging: transfontanelar US, brain computerized tomography (CT), brain 
magnetic resonance imaging (MRI) at the acute phase and during follow-up. 
- Non-neurological complications: pancreatitis, heart dysfunction…. 
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- Medium- and long-term outcome (2-18 years). 
Neurologic evaluation was performed by a pediatric neurologist when abnormalities at the 
initial neurological examination or complementary tests were identified.  
Neurological sequelae were considered “medium-term” when they were present between 4 
weeks and 12 months after clinical onset; complications were considered “long-term” when 
they persisted for more than 1 year after admission.  
Neurocognitive evaluation was performed when medium or long term sequelae were 
identified. In these patients, physiotherapy and neurocognitive intervention were started as 
soon as possible after hospital discharge and continued during the school years. 
- Pathology data of the exitus are also summarized.  
Follow-up was maintained until clinical normalization or at least 2 years after admission. 
3. Results 
The following tables summarize the patients’ characteristics (sex, age at onset), causative 
agent, clinical presentation, diagnostic tests and clinical course of the 25 patients with HUS 
and neurological symptoms at onset.  
Median age at presentation was 2 years 8 months (range 7 months-7 years old). 
As shown in Table 1, sex distribution in HUS patients with neurologic symptoms reveals a 
higher proportion of girls (64%), with a boy/girl rate of 1:1.7; the rate among patients 
without neurologic symptoms was 1:1.2, slightly more frequent in girls.  
Recent history of acute gastroenteritis (D+) was present in 24/25 patients with HUS and 
neurological symptoms at onset, although etiologic agent was only found in blood in 4/25 
(two Salmonella enteritidis and two E. coli). One of these patients presented E coli both in 
blood and urine, and another had Salmonella in blood and E. coli in urine; E. coli was also 
present in urine in another patient. 
The most frequent neurologic sign at onset was drowsiness alone (40%) or together with 
irritability (16%), while irritability alone was present in 10%.  
 
Patient 
 
Age at 
onset 
Sex M / F#
Acute 
Gastro 
enteritis¹
Agent Dialysis Acute neurologic presentation 
1 1yr 3mo M D+ Unknown no 
Accidental traumatic epidural 
hematoma 
2 2yr 3mo F D+ Unknown yes Drowsiness 
3 8mo F D+ Salmonella yes Drowsiness. GTCS. Hyponatremia 
4 7mo F D+ Unknown yes 
Drowsiness  cardiac arrest  
myoclonias. 
Plain EEG within 15 hours 
5 4yr 6mo F D+ Unknown yes GTCS. HBP. Hypoglycemia 
6 1yr 2mo M D- Unknown yes GTCS 
7 3yr 4mo M D+ Unknown no Drowsiness 
8 3yr F D+ Unknown yes 
HBP. Brain edema. 
Irritability and drowsiness 
9 2yr 2mo M D+ Unknown yes 
Neurologic depression. Myoclonic 
seizures 
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10 4yr 6mo M D+ 
Salmonella 
E.coli (urine) 
yes Consciousness decrease. Irritability 
11 1yr 10mo F D+ Unknown yes 
Consciousness decrease. 
Myosis. Pyramidal signs 
12 1yr 6mo F D+ Unknown yes Drowsiness, pyramidal signs 
13 2yr 2mo M D+ Unknown no Irritability-drowsiness 
14 6yr F D+ 
E.Coli (urine 
and blood) 
yes Drowsiness 
15 1yr 2mo M D+ Unknown yes GTCS 
16 3yr 8mo F D+ Unknown yes Drowsiness, irritability 
17 1yr 8mo F D+ Unknown yes Drowsiness. Loss of consciousness 
18 2yr 2mo F D+ Unknown yes GTCS. Anisocoria 
19 3yr 1mo F D+ E.Coli (urine) yes Drowsiness 
20 7yr 4mo F D+ Unknown yes Drowsiness 
21* 3yr F D+ E.Coli yes 
Stupor. Consciousness decrease. 
Slow ocular movements 
22 3yr 11mo M D+ Unknown yes 
Irritability, agitation, drowsiness, 
orolingual dystonia. 
23 4 yr F D+ Unknown yes Drowsiness 
24 12 mo F D+ Unknown yes GTCS 
25 12 mo M D+ Unknown yes GTCS 
GTCS: generalized tonic-clonic seizure; HBP: high blood pressure;#M:male /F:female;*Trip to Argentina 
a few days before acute gastroenteritis  
Table 1. Acute neurologic presentation on HUS context.  
Nine patients suffered seizures at onset (generalized tonic-clonic, tonic or myoclonic 
seizures), which stands for 14% of all HUS patients and 36% of neurologic HUS patients. All 
nine patients survived without important long term sequelae. However, patients presenting 
seizure recurrence (patient 6) or myoclonic seizures during the acute phase (patient 9) 
developed medium term sequelae. 
One patient presented orolingual dystonia shortly after clinical onset with irritability and 
drowsiness; no other patients showed abnormal movements at the acute phase or during 
follow up. 
Eleven children had some neurological complementary test performed: eye funduscopy showed 
fovea erythrosis in patient 4 (exitus), and patient 21 presented delayed and disorganized VEP 
with normal BEAR. Video EEG was abnormal for all the patients who underwent it (5/9), with 
slow background activity; transfontanellar US, BMA Doppler US brain CT and MRI (both in the 
acute phase and during follow-up) findings are summarized in Table 2.  
Brain MRI findings of patients 6 (Figures 1 and 2) and 21 (Figures 3 and 4) are consistent 
with vasculitic lesions due to diffuse hypoxic-ischemic aggression, with cortico-subcortical 
and basal ganglia distribution. Despite these findings, which were persistent along follow-
up, both patients presented a favorable course without important long-term sequelae. 
www.intechopen.com
Haemolytic-Uraemic Syndrome: 
Neurologic Symptoms, Neuroimaging and Neurocognitive Outcome 
 
207 
Patient EEG 
Brain 
ultrasound 
Brain CT 
Brain MRI acute 
phase 
Brain MRI 
control 
4 
Plain EEG 15 
hours after 
onset 
Normal at the 
acute phase. 
Absence of 
supra-tentorial 
pulse 15h after 
onset 
Not performed Not performed Not performed 
6 
Bilateral 
hemispheric 
abnormalities 
Not performed Not performed
Cortico-
subcortical 
atrophy. Putamen 
necrosis 
Putamen 
necrosis 
11 
Combination 
θ,ǂ and ǃ 
waves, without 
paroxysmal 
activity 
Normal Normal Not performed Not performed 
15 
Diffuse slow 
background. 
Left temporal 
paroxysms 
Prominent sulci Not performed Not performed Not performed 
17 
Paradoxal 
reactivity with 
slow 
background and 
slow high 
voltage waves 
in both 
hemispheres,  
no paroxysms
Not performed Not performed Not performed Not performed 
21 Not performed
Bilateral 
hemispheric 
abnormalities, of 
left 
predominance
Multiple 
cortico-
subcortical 
hypointense 
images, 
consistent with 
brain edema 
Basal ganglia 
necrosis and  
cortico-
subcortical 
atrophy, 
consistent with 
vasculitis 
Basal ganglia 
necrosis and  
cortico-
subcortical 
atrophy also 
affecting 
cerebellum 
22 Not performed
Normal brain 
medium artery 
Doppler 
ultrasound 
Not performed
Normal diffusion 
brain MRI 
Not performed 
24 Not performed Not performed Not performed Normal Not performed 
25 Not performed Not performed Normal Not performed Not performed 
 
Table 2. Results of the pathologic tests in patients with HUS and neurologic symptoms at the 
acute phase and MRI control.  
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A 
 
B 
Fig. 1. Brain MRI of patient n. 6, six days after clinical onset.  
T1 (A) and T2 (B) axial sequences, consistent with cortico-subcortical atrophy. Symmetrical 
areas of putamen necrosis.  
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       Figure 2.A          Figure 2.B 
  
Figure 2.C 
Fig. 2. Brain MRI of patient n. 6, fifteen years after clinical presentation. Axial T1 (A) and 
FLAIR (B), and coronal T2 (C) sequences. The bilateral putamen necrotic areas remain 
unchanged compared to the previous study. 
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     Figure 3.A                                Figure 3.B 
 
    Figure 3.C          Figure 3.D 
Fig. 3. Brain MRI of patient n. 21, six days after clinical onset. Coronal  FLAIR (A, B, C and 
D) sequences. Prominence of the convexity sulci and increased ventricular size, consistent 
with cortico-subcortical atrophy. Bilateral hyperintense areas at the basal ganglia. Multiple 
cortico-subcortical supratentorial hyperintensities, more subtle at the cerebellar lobes, 
suggestive of ischemic lesions.  
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          Figure 3.E        Figure 3.F 
 
Figure 3.G 
Fig. 3. Brain MRI of patient n. 21, six days after clinical onset. Axial T2 FS (E, F) and T1 (G) 
sequences.  Prominence of the convexity sulci and increased ventricular size, consistent with 
cortico-subcortical atrophy. Bilateral hyperintense areas at the basal ganglia. Multiple 
cortico-subcortical supratentorial hyperintensities, milder at the cerebellar lobes, suggestive 
of ischemic lesions.  
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     Figure 4.A                    Figure 4.B 
 
                Figure 4.C 
Fig. 4. Brain MRI of patient n. 21, 6 months after clinical onset. Coronal FLAIR sequences 
(Figures A and B).  Increased ventricular size, bilateral hyperintense areas at the basal 
ganglia and multiple cortico-subcortical supratentorial hyperintense images, milder at 
cerebellar lobes, suggestive of subacute ischemic lesions, with laminar cortical necrosis. 
Axial T1 sequence (C) showing basal ganglia necrosis (arrows) and cortico-subcortical 
atrophy. 
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Patient Diagnostic Test Medium-term outcome Long-term outcome 
1 No Normal Normal 
2 No Normal Normal 
3 No Normal Normal 
4 
Transfontanellar 
ultrasound* 
Pathology 
Exitus in the acute phase 
Exitus in the acute 
phase 
5 No Normal Normal 
6 
EEG* 
Brain MRI* 
Renal biopsy. Heart Doppler 
and EKG  
Left hemiplegia 
Hypertensive retinopathy 
Renal function worsening 
Hypertrophic myocardiopathy
Asymptomatic 
 
7 No Normal Normal 
8 Eye funduscopy Normal Normal 
9 
VEP. ERG. EEG* 
Brain MRI*. SPECT* 
Cognitive and language delay 
and epilepsy due to cortical 
dysplasia. 
Consistent with his 
base line 
neurodevelopment 
10 No Normal Normal 
11 
EEG* 
Brain CT 
Slight cognitive delay 
Outside follow-up, 
described as normal 
12 No Normal Normal 
13 No Normal Normal 
14 No Normal Normal 
15 
Transfontanellar ultrasound
EEG* 
Learning disability Normal 
16 No Normal Normal 
17 EEG* Normal Normal 
18 No Normal Normal 
19 No Acute pancreatitis Normal 
20 No Normal Normal 
21 
Brain CT*. Brain MRI* 
EEG*. VEP*. PEAT 
Visual impairment 
 
Slight visual 
impairment Slightly 
unstructured EEG 
22 
Diffusion MRI*. EEG 
Lumbar puncture 
Brain medium artery 
Doppler ultrasound 
Visual impairment 
Cognitive impairment 
Normal 
23 No normal normal 
24 Brain MRI normal normal 
25 Brain CT normal normal 
Table 3. Diagnostic tests, medium- and long-term outcome of patients with neurologic 
symptoms at the acute phase; (*) abnormal test. 
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Five of the 25 patients with neurologic symptoms at the acute phase showed one or more 
medium-term neurological deficits (Table 3): 1/5 hemiparesia, 4/5 mild cognitive 
dysfunction and 2/5 visuo-perception and construction deficits, which almost normalized 
during long-term follow up. Nineteen of the 25 presented normal neurological examination 
at hospital discharge, and one year later.  
Patient 4 died within the first 15 hours after admission, after a rapidly progressive 
neurologic deterioration and respiratory arrest. He presented lower limb myoclonias after 
life rescue. Thorax x-ray revealed right inferior lobe (RIL) pneumonia. Abdomen and 
transfontanellar US were normal. Pathology studies confirmed RIL pneumonia, severe 
segmentary glomerular and tubular nephropathy, acute pancreatitis, lung and heart 
interstitial inflammation, diffuse alveolar damage, intracapillary thrombi in lungs and 
kidneys, brain cortical necrosis with edema and cerebellar granular necrosis. Steptococcus 
pneumoniae was not identified. This represents a mortality of 1.5% of the HUS patients and 
4% of the patients with HUS and neurologic symptoms at onset.  
4. Comments 
HUS is a multisystemic entity; its incidence in Europe has been sporadic in the past, 
although recent migration movements have facilitated a relapse of cases in several countries.  
In general, older patients tend to show milder neurologic symptoms at onset, like 
drowsiness or irritability, while younger patients, especially under 18 months, tend to 
present seizures during the acute phase.  
Physiopathology is not yet well understood, but experimental and in vivo studies (Ren et 
al., 1999; Carter, 1986; Cimolai, 1896) have proved that Escherichia coli VT induces 
thrombopenia through consuming, kidnapping, aggregation and platelet dysfunction 
mechanisms; plasminogen inhibitor activity is also enhanced, and therefore fibrinolysis is 
inhibited. Released factors such as TNF, IL, FvW monomers, free radicals, thromboxane, 
etc., provoke endothelial lesions and vasculitic events in several organs, especially kidneys, 
digestive system and brain (Seth et al., 1896; Miller & Kin, 1987; Montoliu, 1989; Hahn et al., 
1989; Erikson et al., 2001; Steinborn et al., 2004; Rivero et al., 2004). VT receptors are present 
in various troncoencephalic nuclei, the amygdala and the hippocampus, and in the posterior 
root neurons of the ganglia. This suggests VT may induce primary neuronal damage as well 
as a vasculitic lesion (Hahn et al., 1989; Hamano et al., 1993; Rivero et al., 2004). This 
probably happens also at the basal ganglia, especially at putamen nucleae, the most frequent 
localization of CNS lesions (Nakamura et al., 2003). The vasculitic damage (due to the 
diffuse hypoxic-ischemic aggression) observed in our patients was mainly localized at 
cortico-subcortical areas and the basal ganglia, as described in previous reports (Ren et al., 
1999; Akasaka et al., 1999; Garel et al., 2004). Clinical course of patients with these lesions 
was favorable, and MRI lesions became smaller on follow-up controls. Brain MRI sequenced 
controls of patients 6 and 21 reinforce the hypothesis of vasculitic lesion as the main cause of 
tissue damage, although direct neuronal toxicity could not be disclosed (Hahn et al., 1989). 
In contrast with previous reports (Theobald et al., 2001), basal ganglia necrosis has not 
proved to be a bad prognosis factor in our series: our patients did not present 
extrapyramidal signs, as other authors have reported (Di Mario et al., 1987; Barnett et al., 
1995).  
Unfavorable neurologic outcome was formerly correlated with seizures at onset of 
symptoms and plasmapheresis (unnecessary for our patients) at diagnosis (Cimolai et al., 
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1986). The nine patients who presented seizures at onset survived without long-term 
sequelae, whereas the only exitus presented initial drowsiness and rapidly progressive 
neurologic deterioration, without seizures (myoclonias happened after resuscitation 
maneuvers). This was the only patient with neurologic symptoms, acute pancreatitis, 
endocarditis and RIL pneumonia; Streptococcus pneumoniae was not detected (De Loos et al., 
2002; Prestidge & Wong, 2009). Neurologic evaluation and follow-up of patients with CNS 
symptoms allowed early detection of subtle vision dysfunction, visual perception deficit, 
and mild cognitive disabilities.  
Incidence of neurologic symptoms in acute phase of HUS in this group (39%) was similar to 
former descriptive studies (Sheth et al., 1986; Hahn et al., 1989; Garel et al., 2004; Steinborn 
et al., 2004); orolingual dystonia was previously observed, but cortical blindness, 
hallucinations (Cimolai et al., 1896) and cerebellar mutism/anarthria (Mewasingh et al., 
2003) were not observed in our group. A slightly higher prevalence in girls was identified 
(boy/girl rate 1:1.2), as reported by other authors (Cimolai et al., 1986; Rivero et al., 2004; 
Zambrano et al., 2005); this rate is increased to 1:1,7 when regarding the neurologic patients, 
perhaps related to specific auto-immune characteristics.  
It was previously reported that HUS patients with partial seizures tend to present epilepsy 
or abnormal movements after HUS recovery (Dhuna et al., 1992; Hue et al., 1992; Koehl et 
al., 2010). However, none of our patients developed abnormal movements during medium- 
and long-term follow-up, and seizures or EEG abnormalities at the acute phase did not 
determine a poor outcome (only the patient with previously diagnosed cortical dysplasia 
presented focal seizures).  
SHU mortality has decreased in recent years, from 25% in the 1980s to 2% in more recent 
publications (Rivero et al., 2004).  Despite this low mortality rate, a small percentage of 
patients with neurological symptoms at the acute stage subsequently present neurological 
sequelae. In our series of 25 children with neurological symptoms, one patient died and 5 
had medium-term neurological complications (hemiparesia, cognitive delay or visual 
perception deficit). The rates of medium-term neurologic morbidity (20%) and mortality 
(4%) were similar to those of other authors (Hahn et al., 1989; Erikson et al., 2001). Only in 
one patient after 3 years of follow-up were there persistent minor neurological sequelae 
(slight cognitive, visual perception and visual construction impairments), with gradual 
improvement despite the absence of significant changes on MRI and visual evoked 
potentials monitoring. Although neurocognitive impairment is not frequently reported in 
HUS (Roche et al., 2008), neuropsychological evaluation and follow-up of these children, 
especially when basal ganglia (mainly putamen) and cortico-subcortical regions are 
damaged at the initial brain MRI, helps to identify neurocognitive disabilities. Even if they 
are not severe, a good neurofunctional diagnosis and rehabilitation can help patients with 
their school performance and day-to-day life. 
5. Conclusions 
In summary, HUS is not yet completely understood from a physiological point of view. 
The most common neurological manifestations in the acute phase are drowsiness, stupor, 
irritability and convulsions. Neurological morbidity is important: it affects 20% of 
children with acute neurological presentation (8% of all patients with HUS). Seizures at 
presentation were not a risk factor for poor outcome in our series. Electrophysiological 
abnormalities at the acute phase tend to normalize; when they persist, clinical expression 
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is very subtle. Importantly, brain lesions may persist during follow-up despite clinical 
recovery. No clear correlation can be established between MRI findings and long-term 
clinical outcome. Neurocognitive evaluation of children with neurological impairment in 
the context of SHU should be part of the medium- and long-term follow-up in these 
patients.  
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